Open
寶泰生醫成立於2019年，公司致力於伴侶動物免疫治療藥物的研發，目標是成為亞太地區寵物疾病免疫治療領先者。寶泰的研發團隊來自於美國哈佛大學、哥倫比亞大學、美國默克公司等，累積數十年人類藥物開發經驗。過去曾完成四項候選藥物由實驗室到美國人體臨床二期的開發工作。寶泰目前已有全球第一個廣譜性動物癌症治療產品PT001，準備進入臨床試驗。寶泰生目前正在尋求項目/技術平台與全球動物藥品企業的合作機會。
the company is committed to the research and development of companion animal immunotherapy drugs with the goal of becoming a leader in pet disease immunotherapy in the Pan-Asia region. Protect Biotech currently has the world's first broad-spectrum animal cancer treatment product PT001, ready to enter clinical trials
the company is committed to the research and development of companion animal immunotherapy drugs with the goal of becoming a leader in pet disease immunotherapy in the Pan-Asia region. Protect Biotech currently has the world's first broad-spectrum animal cancer treatment product PT001, ready to enter clinical trials